- Published at
- by zacks.com
mixed
mixed
Top Stock Reports for Microsoft, AstraZeneca & BlackRock
MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.
News for AstraZeneca PLC (AZN.L)
- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Faces Competitive Pressure in Blood Pressure Market | AZN Stock News
Jefferies has started coverage on Mineralys Therapeutics (MLYS) with a Hold rating, setting a price target of $15. Mineralys is developing an innovative blood p- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) to Restructure U.S. Vaccine Advisory Committee Amid Trust Issues | AZN Stock News
AstraZeneca (AZN) is poised to be affected by a significant restructuring of the U.S. vaccine advisory process. Recent announcements indicate a complete reconst- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Among Key Players in Pharmaceutical Sector | AZN Stock News
Amidst various pharmaceutical and vaccine companies, AstraZeneca (AZN) stands as a significant player. This company, alongside others in the industry, drives in- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Faces Challenges Amid Public Trust Crisis in Vaccines | AZN Stock News
The issue of vaccine trust is becoming increasingly contentious in the U.S., and AstraZeneca (AZN) finds itself at the center of the discussion. Public confiden- Published at
- by gurufocus.com
positivepositiveAZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News
AstraZeneca (AZN) has commenced the DESTINY-Endometrial01 phase 3 clinical trial, marking the first administration of the study's treatment. This trial is desig- Published at
- by wallstreetpit.com
mixedmixedIonQ Stock Jumps 11% After $1.075 Billion Deal for Oxford Ionics
IonQ Inc. (IONQ) shares rose over 11% to $43.41 in premarket trading after announcing a $1.075 billion acquisition of Oxford Ionics, including $1.065 billion in stock and $10 million in cash, to advance trapped-ion quantum computing and support US-UK technological collaboration. The acquisition accelerates IonQ’s goal to develop fault-tolerant quantum…- Published at
- by gurufocus.com
positivepositiveEye Health Concerns Arise for Diabetes Patients Using AstraZeneca's (AZN) GLP-1 Drugs | AZN Stock News
An observational study has highlighted a potential eye health risk for diabetes patients using GLP-1 medications, including those produced by AstraZeneca (AZN).- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Gains EU Nod for Calquence Regimen in Leukemia Treatment | AZN Stock News
The European Union has granted approval to AstraZeneca's (AZN) Calquence, in combination with venetoclax, with or without obinutuzumab, for treating adults with- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Veteran Joins Perrigo Leadership Team | AZN Stock News
Perrigo has announced that Matt Winterman will become the company's new Executive Vice President, Product Supply, Operations Strategy and Transformation Officer- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Reports Promising Phase 3 Results for Enhertu and Perjeta Combo
Key Highlights: AstraZeneca's (AZN) phase 3 trial reveals significant advancements in HER2-positive metastatic breast cancer treatment. Enhertu and Perje- Published at
- by gurufocus.com
mixedmixedAstraZeneca (AZN) Considered for Potential Pharma Collaborations | AZN Stock News
Truist analyst Asthika Goonewardene has highlighted recent developments in the pharmaceutical sector, following Bristol Myers Squibb's collaboration with BioNTe- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Reports Positive Phase III Trial Results for Breast Cancer Treatment | AZN Stock News
AstraZeneca (AZN) and Daiichi Sankyo have announced promising outcomes from the DESTINY-Breast09 Phase III trial. Their drug combination, ENHERTU plus pertuzuma- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News
AstraZeneca (AZN) has announced promising outcomes from the Phase III SERENA-6 trial, which assessed the effectiveness of its drug camizestrant in treating adva- Published at
- by bloombergquint.com
positivepositiveAstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth
Astrazeneca Pharma India's share price jumped over 8% after the company reported strong fourth-quarter results, showcasing growth across key financial metrics. The pharmaceutical giant's revenue for the quarter increased by 25.3% year-on-year, reaching Rs 480 crore compared to Rs 383 crore in the same period last year.- Published at
- by gurufocus.com
positivepositiveAstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News
Recent trial data highlights the potential of DATROWAY, a TROP2 directed DXd antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca (AZN), in treat- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News
AstraZeneca (AZN) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI, when comb- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News
AstraZeneca (AZN) has announced promising outcomes from its SERENA-6 Phase III clinical trial, highlighting the efficacy of camizestrant when paired with a cycl- Published at
- by gurufocus.com
positivepositiveAstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News
The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky- Published at
- by finance.yahoo.com
neutralneutralDanaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR’s newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to […]